

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BACHMANN *et al.*

Appl. No.: 10/622,087

Filed: July 18, 2003

For: **Amyloid β 1-6 Antigen Arrays**

Confirmation No.: 5998

Art Unit: 1648

Examiner: Homing, M.

Atty. Docket: 1700.0350002/BJD

Second Supplemental Information Disclosure Statement

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08a and PTO/SB/08b are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on April 2, 2004, in connection with the above-captioned application. Copies of documents **AA1-AR1** and **AA2-AH2** are not provided in accordance with the U.S. Patent and Trademark Office pre-OG notice of July 11, 2003, which states that "[t]he Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003." Copies of the remaining documents are provided.

Applicants wish to bring the following matter to the Examiner's attention: WO 02/056905 A2 (listed herein as document **AT4**) corresponds to Applicants' related co-pending Application No. 10/050,898, filed January 18, 2002, published as 2003/017574, previously filed as document **AA3**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Forms PTO/SB/08a and PTO/SB/08b based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated. Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Second Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Fee payment is provided through online credit card payment in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Forms PTO/SB/08a and PTO/SB/08b, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and

Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "B. Del Buono", written over a horizontal line.

Brian J. Del Buono

Attorney for Applicants

Registration No. 42,473

Date: November 27, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	10/622,087
Filing Date	July 18, 2003
First Named Inventor	Martin F. Bachmann
Art Unit	1648
Examiner Name	Michelle Horning
Attorney Docket Number	1700.0350002/BJD

Sheet 1 of 4

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If Known)			
	AA1	US- 4,722,840	02/02/1988	Valenzuela <i>et al.</i>	
	AB1	US- 4,959,314	09/25/1990	Mark <i>et al.</i>	
	AC1	US- 5,143,726	09/01/1992	Thornton <i>et al.</i>	
	AD1	US- 5,565,548	10/15/1996	Neurath <i>et al.</i>	
	AE1	US- 5,698,424	12/16/1997	Mastico <i>et al.</i>	
	AF1	US- 5,916,818	06/29/1999	Irsch <i>et al.</i>	
	AG1	US- 5,928,647	07/27/1999	Rock	
	AH1	US- 5,935,821	08/10/1999	Chatterjee <i>et al.</i>	
	AI1	US- 6,004,763	12/21/1999	Gengoux <i>et al.</i>	
	AJ1	US- 6,054,312	04/25/2000	Larocca <i>et al.</i>	
	AK1	US- 6,180,771 B1	01/30/2001	Thomas <i>et al.</i>	
	AL1	US- 6,231,864	05/15/2001	Birkett	
	AM1	US- 6,380,364 B1	04/30/2002	Mueller <i>et al.</i>	
	AN1	US- 2002/0052311 A1	05/02/2002	Solomon <i>et al.</i>	
	AO1	US- 2002/0064533 A1	05/30/2002	Murray	
	AP1	US- 2002/0081295 A1	06/27/2002	Schiller <i>et al.</i>	
	AQ1	US- 2003/0157479 A1	08/21/2003	Bachmann <i>et al.</i>	
	AR1	US- 2003/0175290 A1	09/18/2003	Renner <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ³ Kind Code ⁵ (In known)				
	AS1	EP 0 038 154 A1	10/21/1981	Garman <i>et al.</i>		
	AT1	WO 90/15878 A1	12/27/1990	Stanworth <i>et al.</i>		
	AU1	EP 0 578 293 A1	01/12/1994	Van der Zee <i>et al.</i>		
	AV1	EP 0 385 610 B1	03/16/1994	Rowlands <i>et al.</i>		
	AW1	EP 0 465 081 B1	04/20/1994	Kossovsky <i>et al.</i>		
	AY1	EP 0 283 505 B1	07/06/1994	Hunter <i>et al.</i>		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Complete If Known

(Use as many sheets as necessary)

4

10/622.087

July 18, 2003

Martin F. Bachmann

1648

Michelle Horning

1700.0350002/B.JD

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov/ MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard 3.13). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 3.16 if possible. *Applicant is to place a check mark in the appropriate box. *English and Japanese titles of the document. This collection of information is required by 37 CFR 1.57 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Patent Center, 401, Alexandria, VA 22314-1450. DO NOT WRITE IN THESE SPACES. *Applicant's address for correspondence. *US Patent and Trademark Office, Box 1450, Alexandria, VA 22314-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4**Complete If Known**

Application Number

10/622.087

Filing Date

July 18, 2003

First Named Inventor

Martin F. Bachmann

Art Unit

1648

Examiner Name _____

Michelle Horning

Attorney Docket Number

1700.0350002/B.ID

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Kind Code ³ (in known)				
	AS3	WO 99/57289 A2	11/11/1999	Pumpens <i>et al.</i>		
	AT3	WO 00/23955 A1	04/27/2000	Schiller <i>et al.</i>		
	AU3	WO 00/32227 A2	06/08/2000	Renner <i>et al.</i>		
	AV3	WO 00/50461 A1	08/31/2000	Friede <i>et al.</i>		
	AW3	WO 01/53457 A2	07/26/2001	Srivastava		
	AY3	WO 01/62284 A2	08/30/2001	Birk <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04.

form with next communication to applicant. Applicant's unique citation designation number (optional). * See Kinda Codes or USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/622,087
				Filing Date	July 16, 2003
				First Named Inventor	Martin F. Bachmann
				Art Unit	1648
				Examiner Name	Michelle Horning
Sheet	1	of	8	Attorney Docket Number	1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Adhin, M.R., <i>et al.</i> , "Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification," <i>Virology</i> 170(1):238-242, Academic Press, Inc. (1989)	
	NPL2	Ansel, K.M., <i>et al.</i> , "A chemokine-driven positive feedback loop organizes lymphoid follicles," <i>Nature</i> 406(6793):309-314, Nature Publishing Group (2000)	
	NPL3	Ansel, K.M., <i>et al.</i> , "In Vivo-activated CD4 T Cells Upregulate CXC Chemokine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines," <i>J. Exp. Med.</i> 190(8):1123-1134, The Rockefeller University Press (1999)	
	NPL4	Bachmann, M.F., and Zinkernagel, R.M., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunology Today</i> 17(12):553-558, Elsevier Science Ltd. (1996)	
	NPL5	Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Annu. Rev. Immunol.</i> 15:235-270, Annual Reviews, Inc. (1997)	
	NPL6	Bachmann, M.F., <i>et al.</i> , "Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 26(11):2595-2600, VCH Verlagsgesellschaft mbH (1996)	
	NPL7	Bachmann, M.F., <i>et al.</i> , "TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation," <i>J. Exp. Med.</i> 189(7):1025-1031, The Rockefeller University Press (1999)	
	NPL8	Bard, F. <i>et al.</i> , "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nat. Med.</i> 6(8):916-919, Nature Publishing Company (2000)	
	NPL9	Bass, S., and Yang, M., "Expressing cloned genes in <i>Escherichia coli</i> ," in <i>Protein Function: A Practical Approach</i> , 2nd ed., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, 175:29-55, (1997)	
	NPL10	Bowie, J.U., <i>et al.</i> , "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> 247(4948):1306-1310, (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/622,087
				Filing Date	July 18, 2003
				First Named Inventor	Martin F. Bachmann
				Art Unit	1648
				Examiner Name	Michelle Horning
Sheet	2	of	8	Attorney Docket Number	1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	NPL11	Brown, W.L., <i>et al.</i> , "RNA bacteriophage capsid-mediated drug delivery and epitope presentation," <i>Intervirology</i> 45(4-6):371-380, S. Karger AG Basel (2002)		
	NPL12	Cesareni, G., "Peptide display on filamentous phage capsids: A new powerful tool to study protein-ligand interaction," <i>FEBS Lett.</i> 307(1):66-70, Elsevier Science Publishers B.V. (1992)		
	NPL13	Chackerian, B., <i>et al.</i> , "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," <i>Proc Natl. Acad. Sci USA</i> 96(5):2373-2378, (1999)		
	NPL14	Cramer, R. and Suter, M., "Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production," <i>Gene</i> 137(1):69-75, Elsevier Science Publishers B.V. (1993)		
	NPL15	de la Cruz, V.F., <i>et al.</i> , "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <i>J. Biol. Chem.</i> 263:4318-4322, The American Society for Biochemistry and Molecular Biology, Inc. (1988)		
	NPL16	Dodart J.-C., <i>et al.</i> , "Immunotherapy for Alzheimer's disease: will vaccination work?," <i>TRENDS in Molecular Medicine</i> 9(3):85-87, (2003)		
	NPL17	Donnelly, J.J., <i>et al.</i> , "DNA Vaccines," <i>Annu. Rev. Immunol.</i> 15:617-648, Annual Reviews, Inc. (1997)		
	NPL18	Fehr, T., <i>et al.</i> , "T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles," <i>Proc. Natl. Acad. Sci</i> 95(16):9477-9481, (1998)		
	NPL19	Fehr, T., <i>et al.</i> , "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J Exp. Med.</i> 185(10):1785-1792, The Rockefeller University Press (1997)		
	NPL20	Frenkel, D., <i>et al.</i> , "Generation of auto-antibodies towards Alzheimer's disease vaccination," <i>Vaccine</i> 19(17-19):2615-2619, Elsevier Science, Ltd. (2001)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				<i>Application Number</i>	10/822,087
				<i>Filing Date</i>	July 18, 2003
				<i>First Named Inventor</i>	Martin F. Bachmann
				<i>Art Unit</i>	1548
				<i>Examiner Name</i>	Michelle Horning
Sheet	3	of	8	<i>Attorney Docket Number</i>	1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL21	Frenkel, D., <i>et al.</i> , "Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration," <i>PNAS</i> 97(21):11455-11459, (2000)	
	NPL22	Frolov, I., <i>et al.</i> , "Alphavirus-based expression vectors: strategies and applications," <i>Proc. Natl. Acad. Sci</i> 93(21):11371-11377, (1996)	
	NPL23	Gilman, S., <i>et al.</i> , "Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial," <i>Neurology</i> 64(9):1553-1562, (2005)	
	NPL24	Golmohammadi, R., <i>et al.</i> , "The crystal structure of bacteriophage Q β at 3.5Å resolution," <i>Structure</i> 4(5):543-554, Current Biology, Ltd. (1996)	
	NPL25	Harris, S.J., <i>et al.</i> , "Prediction of murine MHC class I epitopes in a major house dust mite allergen and induction of T1-type CD8+ T cell responses," <i>International Immunology</i> 9(2):273-280, (1997)	
	NPL26	Hedrick, J.A., and Zlotnik, A., "Identification and Characterization of a Novel β Chemokine Containing Six Conserved Cysteines," <i>J. Immunol.</i> 159(4):1589-1593, The American Association of Immunologists (1997)	
	NPL27	Hilleman, M.R., "Six decades of vaccine development - a personal history," <i>Nat. Med. Vaccine Suppl.</i> 4(5 Suppl):507-514, (1998)	
	NPL28	Holtzman, D.M., <i>et al.</i> , "Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <i>Advanced Drug Delivery Reviews</i> 54(12):1603-1613, Elsevier Science (2002)	
	NPL29	Iannolo, G., <i>et al.</i> , "Construction, Exploitation and Evolution of a New Peptide Library Displayed at High Density by Fusion to the Major Coat Protein of Filamentous Phage," <i>Biol. Chem.</i> 378(6):517-521, Walter de Gruyter & Co. (1997)	
	NPL30	Iannolo, G., <i>et al.</i> , "Modifying Filamentous Phage Capsid: Limits in the Size of the Major Capsid Protein," <i>J. Mol. Biol.</i> 248(4):835-844, Academic Press, Ltd. (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known		
				<i>Application Number</i>	10/622,087	
				<i>Filing Date</i>	July 18, 2003	
				<i>First Named Inventor</i>	Martin F. Bachmann	
				<i>Art Unit</i>	1648	
				<i>Examiner Name</i>	Michelle Horning	
Sheet	4	of	8	<i>Attorney Docket Number</i>		1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL31	Janus, C., "Vaccines for Alzheimer's disease: how close are we?," <i>CNS Drugs</i> 17(7):457-474, Adis Data Information (2003)	
	NPL32	Jegerlehner, A., <i>et al.</i> , "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," <i>Vaccine</i> 20(25-26):3104-3112, Elsevier Science, Ltd. (2002)	
	NPL33	Kastelein, R.A. <i>et al.</i> , "Effect of the sequence upstream from the ribosome-binding site on the yield of protein from the cloned gene for phage MS2 coat protein," <i>Gene</i> 23(3):245-254, Elsevier (1983)	
	NPL34	Klovins, J., <i>et al.</i> , "Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages," <i>Journal of general Virology</i> 83(Pt 6):1523-1533, SGM (2002)	
	NPL35	Kovacsovics-Bankowski, M., <i>et al.</i> , "Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages," <i>Proc. Natl. Acad. Sci. USA</i> 90:4942-4946, National Academy Press (1993)	
	NPL36	Kozlovskaya, T.M., <i>et al.</i> , "Recombinant RNA phage Q β capsid particles synthesized and self-assembled in <i>Escherichia coli</i> ," <i>Gene</i> 137(1):133-137, Elsevier Science Publishers B.V. (1993)	
	NPL37	Kozlovskaya, T.M., <i>et al.</i> , "RNA Phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Intervirology</i> 39(1-2):9-15, S. Karger AG (1996)	
	NPL38	Kozlovskaya, T.M., <i>et al.</i> , "Formation of capsid-like structures as a result of the expression of a cloned envelope protein gene from RNA-containing bacteriophage," <i>Dokl. Akad. Nauk. SSSR</i> 287:452-455, Erivan Akademiia Nauk Amianskoi Ssr (1986)	
	NPL39	Kratz, P.A., <i>et al.</i> , "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci</i> 96(5):1915-1920, (1999)	
	NPL40	Lechner, F., <i>et al.</i> , "Virus-like particles as a modular system for novel vaccines," <i>Intervirology</i> 45(4-6):212-217, S. Karger AG Basel (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				<i>Application Number</i>	10/622,087	
				<i>Filing Date</i>	July 18, 2003	
				<i>First Named Inventor</i>	Martin F. Bachmann	
				<i>Art Unit</i>	1648	
				<i>Examiner Name</i>	Michelle Horning	
Sheet	5	of	8	<i>Attorney Docket Number</i>		1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL41	Lim, F., <i>et al.</i> , "The RNA-binding Site of Bacteriophage Q β Coat Protein," <i>J. Biol. Chem.</i> 271(50):31839-31845, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL42	Loktev, V.B., <i>et al.</i> , "Design of immunogens as components of a new generation of molecular vaccines," <i>J. Biotechnol.</i> 44(1-3):129-37, Elsevier Science (1996)	
	NPL43	Lo-Man, R., <i>et al.</i> , "A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant," <i>Eur. J. Immunol.</i> 28(4):1401-1407, Wiley-VCH Verlag GmbH (1998)	
	NPL44	McGeer, P.L., McGeer, E., "Is there a future for vaccination as a treatment for Alzheimer's disease?," <i>Neurobiology of Aging</i> 24(3):391-395, (2003)	
	NPL45	Minenkova, O.O., <i>et al.</i> , "Design of specific immunogens using filamentous phage as the carrier," <i>Gene</i> 128(1):85-88, Elsevier Science Publishers B.V. (1993)	
	NPL46	NCBI Entrez, GenBank Report, Accession No. AAA16663, from Kozlovskaya, T.M., <i>et al.</i> (March 1994)	
	NPL47	NCBI Entrez, GenBank Report, Accession No. AAC14699, from Beekwilder, M.J., <i>et al.</i> (April 1998)	
	NPL48	NCBI Entrez, GenBank Report, Accession No. AAC14704, from Beekwilder, M.J., <i>et al.</i> (April 1998)	
	NPL49	NCBI Entrez, GenBank Report, Accession No. CAA30374, from Inokuchi, Y., <i>et al.</i> (February 1999)	
	NPL50	NCBI Entrez, GenBank Report, Accession No. NP_040754, from Inokuchi, Y., <i>et al.</i> (June 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/622,087
				Filing Date	July 16, 2003
				First Named Inventor	Martin F. Bachmann
				Art Unit	1648
				Examiner Name	Michelle Horning
Sheet	6	of	8	Attorney Docket Number	1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL51	NCBI Entrez, GenBank Report, Accession No. P03611, from Weber, K., <i>et al.</i> (November 1997)	
	NPL52	NCBI Entrez, GenBank Report, Accession No. VCBPM2, from Min Jou, W., <i>et al.</i> (January 2001)	
	NPL53	NCBI Entrez, GenBank Report, Accession No. VCBPQB, from Maita, T., and Konigsberg, W. (December 1993)	
	NPL54	Neurath, A.R., <i>et al.</i> , "Hepatitis B Virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail," <i>Mol. Immunol.</i> 26:53-62, Pergamon Press (1989)	
	NPL55	Ni, C.-Z., <i>et al.</i> , "Crystal structure of the coat protein from the GA bacteriophage: Model of the unassembled dimer," <i>Protein Sci.</i> 5:2485-2493, Cambridge University Press (1996)	
	NPL56	Nieland, J.D., <i>et al.</i> , "Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response," <i>Journal of Cellular Biochemistry</i> 73(2):145-152, Wiley-Liss Inc. (1999)	
	NPL57	Ormstad, H., <i>et al.</i> , "Airborne house dust particles and diesel exhaust particles as allergen carriers," <i>Clinical and Experimental Allergy</i> 28(6):702-708, Blackwell Science Ltd. (1998)	
	NPL58	O'Shea, E.K., <i>et al.</i> , "Evidence That the Leucine Zipper Is a Coiled Coil," <i>Science</i> 243(4890):538-542, American Association for the Advancement of Science (1989)	
	NPL59	O'Shea, E.K., <i>et al.</i> , "Mechanism of Specificity in the Fos-Jun Oncoprotein Heterodimer," <i>Cell</i> 68(4):699-708, Cell Press (1992)	
	NPL60	Pasek, M., <i>et al.</i> , "Hepatitis B virus genes and their expression in E. coli," <i>Nature</i> 282(5739):575-578, Macmillan Journals Ltd. (1979)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known		
				Application Number	10/622,087	
				Filing Date	July 18, 2003	
				First Named Inventor	Martin F. Bachmann	
				Art Unit	1648	
				Examiner Name	Michelle Horning	
Sheet	7	of	8	Attorney Docket Number		1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL61	Perham, R.N., <i>et al.</i> , "Engineering a peptide epitope display system on filamentous bacteriophage," <i>FEMS Microbiol. Rev.</i> 17(1-2):25-31, Elsevier Science Publishers on behalf of the Federation of European Microbiological Societies (1995)	
	NPL62	Petrenko, V.A., <i>et al.</i> , "A library of organic landscapes on filamentous phage," <i>Protein Engin.</i> 9(9):797-801, Oxford University Press (1996)	
	NPL63	Priano, C., <i>et al.</i> , "A Complete Plasmid-based Complementaion System for RNA Coliphage Q β : Three Proteins of Bacteriophages Q β (Group III) and SP (Group IV) can be Interchanged," <i>J. Mol. Biol.</i> 249(2):283-297, Academic Press, Ltd. (1995)	
	NPL64	Raychaudhuri, S., and Rock, K.L., "Fully mobilizing host defense: Building better vaccines," <i>Nat. Biotechnol.</i> 16(11):1025-1031, Nature America, Inc. (1998)	
	NPL65	Robinson, C.R., and Sauer, R.T., "Optimizing the stability of single-chain proteins by linker length and composition mutagenesis," <i>PNAS</i> 95(11):5929-5934, National Academy of Science (1998)	
	NPL66	Roesch, P.L., and Blomfield, I.C., "Leucine alters the interaction of the leucine-responsive regulatory protein (Lrp) with the <i>trm</i> switch to stimulate site-specific recombination in <i>Escherichia coli</i> ," <i>Mol. Microbiol.</i> 27(4):751-761, Blackwell Science, Ltd. (1998)	
	NPL67	Roher, A.E., <i>et al.</i> , "Isolation and Chemical Characterization of Alzheimer's Disease Paired Helical Filament Cytoskeletons: Differentiation from Amyloid Plaque Core Protein," <i>J. Cell Biol.</i> 107(6 Pt 2):2703-2716, The Rockefeller University Press (1988)	
	NPL68	Roher, A.E., <i>et al.</i> , "Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue," <i>J. Neurochem.</i> 61(5):1916-1926, Raven Press, Ltd. (1993)	
	NPL69	Romagnani, S., "The Th1/Th2 paradigm," <i>Immunol. Today</i> 18(6):263-266, Elsevier Science Ltd. (1997)	
	NPL70	Schenk, D., <i>et al.</i> , "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <i>Nature</i> 400(6740):173-177, Nature Publishing Group (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known		
				Application Number	10/622,087	
				Filing Date	July 16, 2003	
				First Named Inventor	Martin F. Bachmann	
				Art Unit	1648	
				Examiner Name	Michelle Horning	
Sheet	8	of	8	Attorney Docket Number		1700.0350002/BJD

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL71	Selkoe, D.J., "Translating cell biology into therapeutic advances in Alzheimer's disease," <i>Nature</i> 399(6738 Suppl):A23-A31, Nature Publishing Group (1999)	
	NPL72	Sturchler-Pierrat, C., et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>Proc. Natl. Acad. Sci. USA</i> 94(24):13287-13292, National Academy Press (1997)	
	NPL73	Townsend, A., and Bodmer, H., "Antigen recognition by class I-restricted T lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624, Annual Reviews, Inc. (1989)	
	NPL74	Ulrich, R., et al., "Core particles of hepatitis B virus as carrier for foreign epitopes," <i>Adv. Virus Res.</i> 50:141-182, Academic Press (1998)	
	NPL75	Vasiljeva, I., et al., "Mosaic Q β coats as a new presentation model," <i>FEBS Lett.</i> 431(1):7-11, Federation of European Biochemical Societies (1998)	
	NPL76	Willis, A.E., et al., "Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage," <i>Gene</i> 128(1):79-83, Elsevier Science Publishers B.V. (1993)	
	NPL77	Witherell, G.W., and Uhlenbeck, O.C., "Specific RNA Binding by Q β Coat Protein," <i>Biochemistry</i> 28(1):71-76, American Chemical Society (1989)	
	NPL78	Witte, L., et al., "Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy," <i>Cancer and Metastasis Reviews</i> 17(2):155-161, Kluwer Academic Publishers (1998)	
	NPL79	Wynne, S.A., et al., "The Crystal Structure of the Human Hepatitis B Virus Capsid," <i>Mol. Cell</i> 3(6):771-780, Cell Press (1999)	
	NPL80	Zhou, S., and Standing, D.N., "Cys Residues of the Hepatitis B Virus Capsid Protein Are Not Essential for the Assembly of Viral Core Particles but Can Influence Their Stability," <i>J. Virol.</i> 66(9):5393-5398, American Society for Microbiology (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.